Recent news from Journal of Clinical Oncology about HR+/HER2-negative breast cancer – ASCO

ASCO (American Society of Clinical Oncology) shared a post on X/Twitter:

”Recent news from Journal of Clinical Oncology: Ribociclib + endocrine therapy represents a potential new 1L option for patients with HR+/HER2-negative advanced breast cancer.”

Source: ASCO/X

ASCO (American Society of Clinical Oncology) is a leading professional organization representing nearly 45,000 physicians and oncology specialists worldwide, dedicated to cancer care. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, ASCO is committed to advancing cancer research, education, prevention, and high-quality patient care.